Welcome to our dedicated page for Ironwood SEC filings (Ticker: IRWD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
MCCOURT Thomas A reported acquisition or exercise transactions in this Form 4 filing.
IRONWOOD PHARMACEUTICALS INC reported that Chief Executive Officer Thomas A. McCourt received a grant of 409,836 shares of Class A Common Stock as a restricted stock unit award. This annual performance award vests in three equal installments of 33.33% on each approximate anniversary of the grant.
Following this award, McCourt directly holds 1,898,838 shares of Class A Common Stock. The grant is compensation-related and was recorded at no cash purchase price per share.
Ironwood Pharmaceuticals, Inc. reported that it has met the liquidity conditions tied to the “Maturity Date” definition in its existing Credit Agreement with Wells Fargo Bank, National Association, as administrative agent. As a result, the revolving credit facility’s maturity date remains December 31, 2028, under the current terms of the Credit Agreement.
Ironwood Pharmaceuticals focuses on gastrointestinal and rare diseases, built around LINZESS and its apraglutide pipeline. The company co-commercializes LINZESS for IBS-C and chronic constipation with AbbVie in the U.S. and relies on partners such as AbbVie, Astellas and AstraZeneca globally.
Through its VectivBio acquisition, Ironwood is advancing apraglutide for short bowel syndrome; after positive Phase III data, the FDA required a confirmatory Phase III trial (STARS-2), with site initiations expected in the second quarter of 2026. Ironwood ceased development of IW-3300 after Phase II results.
Revenue concentration is high, with the U.S. contributing 97.7% of 2025 revenue and LINZESS collaborations comprising substantially all revenue. Government pricing pressure is rising: LINZESS was selected for Medicare price negotiation, and its Maximum Fair Price from 2027 will be $136 for a 30-day supply, alongside a LINZESS list price cut effective January 1, 2026.
Ironwood Pharmaceuticals Chief Legal Officer John Minardo reported automatic sales of 36,492 shares of Class A common stock to cover tax withholding on vested restricted stock units. These open-market transactions occurred on February 23 and 24 at weighted average prices of $3.81 and $3.66 per share, within disclosed intraday price ranges.
After these sell-to-cover trades, Minardo directly held 363,886 Ironwood shares. The filing notes that the sales were executed automatically to satisfy tax obligations and did not represent discretionary trading decisions.
Ironwood Pharmaceuticals SVP and CMO Michael Shetzline reported automatic share sales to cover taxes on vesting restricted stock units. On Class A Common Stock and Common Stock, he sold a total of 32,582 shares in open-market transactions at weighted average prices around $3.81 and $3.66 per share. These sales were executed solely to satisfy tax withholding obligations and were not discretionary trades, and he continued to hold 521,425 shares afterward.
IRONWOOD PHARMACEUTICALS INC Chief Commercial Officer Tammi L. Gaskins reported automatic sales of Class A common stock to cover taxes on vesting restricted stock units. She sold 10,287 shares on February 23 at a weighted average price of $3.81 and 11,239 shares on February 24 at a weighted average price of $3.66, in open-market transactions. The filing states these were mandatory “sell to cover” transactions for tax withholding and not discretionary trades. After these sales, she held 213,738 shares of Ironwood common stock directly.
Ironwood Pharmaceuticals Chief Executive Officer Thomas A. McCourt reported automatic sales of Class A Common Stock to cover tax withholding from vested restricted stock units. On February 23 and 24, 2026, a total of 198,283 shares were sold in open-market transactions classified as non-derivative sales.
The filing notes these were sell-to-cover transactions executed automatically to satisfy tax obligations and did not represent discretionary trades by McCourt. Weighted average sale prices were reported, with shares on one day sold between $3.70 and $4.05 and on the other between $3.60 and $3.73. Following the February 24 sale, he directly held 1,489,002 shares. A footnote also records his acquisition of 4 shares under the company’s employee stock purchase plan on December 31, 2025.
IRONWOOD PHARMACEUTICALS INC Chief Financial Officer Gregory S. Martini reported automatic stock sales to cover taxes tied to restricted stock vesting. On February 23, he sold 10,487 shares of Class A common stock at a weighted-average price of $3.81 per share in open-market transactions within a $3.70–$4.05 range. On February 24, he sold an additional 11,457 shares at a weighted-average price of $3.66 per share within a $3.60–$3.73 range. The filing states these sales were executed automatically solely to satisfy tax withholding obligations and were not discretionary trades. After these transactions, Martini directly owned 160,601 shares of Ironwood Class A common stock.
IRONWOOD PHARMACEUTICALS INC principal accounting officer Ronald Silver reported automatic sales of 24,173 Class A common shares to cover tax withholding obligations from vesting restricted stock units. The transactions involved 11,552 shares on February 23, 2026 at a weighted average price of $3.81 and 12,621 shares on February 24, 2026 at a weighted average price of $3.66. The prices reflect multiple trades within disclosed ranges. After these tax-related, non-discretionary sales, Silver directly held 252,636 shares of Ironwood Pharmaceuticals common stock.
Ironwood Pharmaceuticals reported fourth-quarter and full-year 2025 results and reaffirmed a strong 2026 outlook. For 2025, total revenue was $296.2M, GAAP net income was $24.0M and adjusted EBITDA reached $138.1M. The company generated $127M in operating cash flow and ended the year with $215.5M in cash and cash equivalents.
LINZESS delivered 11% full-year EUTRx demand growth, remaining the leading U.S. prescription brand for IBS-C and CIC. For 2026, Ironwood expects U.S. LINZESS net sales of $1.125–$1.175B, total revenue of $450–$475M and adjusted EBITDA of more than $300M, while it advances the apraglutide Phase 3 STARS-2 trial in short bowel syndrome with intestinal failure.